medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2016, Number 1

<< Back Next >>

Neumol Cir Torax 2016; 75 (1)

First Mexican Consensus on Idiopathic Pulmonary Fibrosis

Mejía M, Buendía-Roldan I, Mateos-Toledo H, Estrada A, Espinoza-Hernández M, Juárez-Hernández F, Vargas-Domínguez C, Selman M

Language: Spanish
References: 96
Page: 32-51
PDF size: 1802.25 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev 2013;22(128):158-162. doi: 10.1183/09059180.00001213.

  2. Travis WD, Costabel U, Hansell DM, et al.; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188(6):733-748. doi: 10.1164/rccm.201308-1483ST.

  3. Raghu G, Collard HR, Egan JJ, et al.; ATS/ERS/JRS/ ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788-824. doi: 10.1164/rccm.2009-040GL.

  4. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183(4):431-440. doi: 10.1164/ rccm.201006-0894CI.

  5. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157(1):199-203.

  6. Coultas DB, Hughes MP. Accuracy of mortality data for interstitial lung diseases in New Mexico, USA. Thorax 1996;51(7):717-720.

  7. Karakatsani A, Papakosta D, Rapti A, et al.; Hellenic Interstitial Lung Diseases Group. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009;103(8):1122- 1129. doi: 10.1016/j.rmed.2009.03.001.

  8. Thomeer MJ, Costabe U, Rizzato G, Poletti V, Demedts M. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl 2001;32:114s-118s.

  9. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150(4):967-972.

  10. Curbelo P. Encuesta de EPID en Latinoamérica–ALAT 2013. Respirar 2013;5: 5-8.

  11. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2(7):566-572. doi: 10.1016/ S2213-2600(14)70101-8.

  12. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137(1):129-137. doi: 10.1378/chest.09-1002.

  13. Von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med 2003;97(4):428-435.

  14. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006;61(11):980-985.

  15. Caminati A, Madotto F, Cesana G, Conti S, Harari S. Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev 2015; 24(137):436-444. doi: 10.1183/16000617.0040-2015.

  16. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013;5:483-492. doi: 10.2147/ CLEP.S54815.

  17. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011;66(6):462-467. doi: 10.1136/thx.2010.148031.

  18. Xaubet A, Ancochea J, Bollo E, et al.; Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. Arch Bronconeumol 2013;49(8):343-353. doi: 10.1016/j.arbres. 2013.03.011.

  19. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378(9807):1949-1961. doi: 10.1016/ S0140-6736(11)60052-4.

  20. Xaubet A, Ancochea J, Blanquer R, et al.; Grupo de Investigación en Enfermedades Pulmonares Intersticiales Difusas. Área de Técnicas y Transplante. SEPAR. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas. Arch Bronconeumol 2003; 39(12):580-600.

  21. Barreto-Rodríguez JO, Mejía M, Buendía-Roldán I. Panorama actual de la fibrosis pulmonar idiopática en México. Neumol Cir Torax 2015;74(4):256-261.

  22. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLos ONE 2007; 2(5):e482

  23. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-664.

  24. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183(4):431-440. doi: 10.1164/ rccm.201006-0894CI.

  25. García-Sancho Figueroa MC, Carrillo G, Pérez-Padilla R, et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir Med 2010;104(2):305-309. doi: 10.1016/j.rmed.2009.08.013

  26. García-Sancho MC, Buendía-Roldán I, Fernández-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 2011;105(12):1902-1907. doi: 10.1016/j. rmed.2011.08.022.

  27. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153(6):1194- 1217. doi: 10.1016/j.cell.2013.05.039.

  28. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med 2014;189(10):1161-1172. doi: 10.1164/ rccm.201312-2221PP.

  29. Raghu G, Rochwerg B, Zhang Y, et al.; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015;192(2):e3–e19 doi: 10.1164/ rccm.201506-1063ST.

  30. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157(4 Pt 1):1301-1315.

  31. Sverzellati N. Highlights of HRCT imaging in IPF. Respir Res 2013;14 Suppl 1:S3. doi: 10.1186/1465-9921-14-S1-S3.

  32. Lynch DA, Godwin JD, Safrin S, et al.; Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005;172(4):488-493.

  33. Sundaram B, Gross BH, Martinez FJ, Oh E, et al. Accuracy of high-resolution CT in the diagnosis of diffuse lung disease: effect of predominance and distribution of findings. AJR Am J Roentgenol 2008;191(4):1032-1039. doi: 10.2214/AJR.07.3177.

  34. Wells AU. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)--practical implications. Respir Res 2013;14 Suppl 1:S2. doi: 10.1186/1465-9921-14-S1-S2.

  35. Hodnett PA, Naidich DP. Fibrosing interstitial lung disease. A practical high-resolution computed tomography- based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med 2013;188(2):141-149. doi: 10.1164/rccm.201208-1544CI.

  36. Wuyts WA, Cavazza A, Rossi G, Bonella F, Sverzellati N, Spagnolo P. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic? Eur Respir Rev 2014;23(133):308-319. doi: 10.1183/09059180.00004914.

  37. Meyer KC, Raghu G, Baughman RP, et al.; American Thoracic Society Committee on BAL in Interstitial Lung Disease. An Official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185(9):1004-1014. doi: 10.1164/rccm.201202-0320ST.

  38. Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179(11):1043- 1047. doi: 10.1164/rccm.200808-1313OC.

  39. Morell F, Villar A, Montero MA, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013;1(9):685-694. doi: 10.1016/ S2213-2600(13)70191-7.

  40. Babiak A, Hetzel J, Krishna G, et al. Transbronchial cryobiopsy: a new tool for lung biopsies. Respiration 2009;78(2):203-208. doi: 10.1159/000203987.

  41. Fischer A, Antoniou KM, Brown KK, et al.; ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46(4):976-987. doi: 10.1183/13993003.00150-2015.

  42. Moua T, Zamora Martínez AC, Baqir M, Vassallo R, Limper AH, Ryu JH. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 2014;15:154. doi: 10.1186/s12931-014-0154-6.

  43. Papanikolaou I, Drakopanagiotakis F, Polychronopoulos VS. Acute exacerbations of interstitial lung diseases. Curr Opin Pulm Med 2010;16(5): 480-486. doi: 10.1097/ MCP.0b013e32833ae49d.

  44. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37(2):356-363. doi: 10.1183/09031936.00159709.

  45. Collard HR, Moore BB, Flaherty KR, et al.; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176(7):636-643.

  46. Judge EP, Fabre A, Admali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012; 40(1):93- 100 doi: 10.1183/09031936.00115511.

  47. Antoniou KA, Wells AU. Acute exacerbation of idiopathic pulmonary fibrosis. Respiration 2013;86(4):265-274. doi: 10.1159/000355485.

  48. Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011;38(1):176-183. doi: 10.1183/09031936.00114010.

  49. Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013;144(1):234-240. doi: 10.1378/chest.12-2403.

  50. Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 2010;15(2):265- 271. doi: 10.1111/j.1440-1843.2009.01676.x.

  51. Cottin V, Nunes H, Brillet PY, et al; Groupe d’Étude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26(4): 586-593.

  52. Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136(1):10-15. doi: 10.1378/chest.08-2306.

  53. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007;175(9):875-880.

  54. Proceedings of the 4th World Symposium on Pulmonary Hypertension, February 2008, Dana Point, California, USA. J Am Coll Cardiol 2009;54(1 Suppl):S1-S117.

  55. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013;62(25 Suppl):D109-D116. doi: 10.1016/j. jacc.2013.10.036.

  56. Han MK, Bach DS, Hagan PG, et al.; IPFnet Investigators. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013;143(6):1699-1708. doi: 10.1378/ chest.12-1594.

  57. Zimmermann GS, von Wulffen W, Huppmann P, et al. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology 2014;19(5):700-706. doi: 10.1111/resp.12294.

  58. Onda N, Tanaka Y, Hino M, Gemma A. Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis. Respir Med Case Rep 2014;14:19-23. doi: 10.1016/j.rmcr.2014.11.008.

  59. Hallowell RW, Reed RM, Fraig M, Horton MR, Girgis RE. Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. Pulm Circ 2012; 2(1):101-106. doi: 10.4103/2045-8932.94842.

  60. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 16181):5-8.

  61. Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 2015;147(1):157-164 doi: 10.1378/chest.14-0359.

  62. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365(5):395-409. doi: 10.1056/ NEJMoa1102873.

  63. Savarino E, Carbone R, Marabotto E, et al. Gastrooesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J 2013; 42(5):1322-1331. doi: 10.1183/09031936.00101212.

  64. Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophagealnreflux disease in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158(6):1804-1808.

  65. Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012;39(2):352-358. doi: 10.1183/09031936.00050911.

  66. Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2012; 39: 344-5. doi: 10.1183/09031936.00099910

  67. Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011;66(3):226-231. doi: 10.1136/ thx.2010.137190.

  68. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184(12):1390-1394. doi: 10.1164/rccm.201101- 0138OC.

  69. Lee JS, Collard HR, Anstrom KJ, et al.; IPFnet Investigators. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013;1(5): 369-376. doi: 10.1016/S2213-2600(13)70105-X.

  70. Buendía-Roldan I, Mejía M, Mateos-Toledo H, et al. Valoración de peso corporal de pacientes con enfermedades intersticiales. XXVII Congreso Venezolano de Neumología y Cirugía Torácica. Porlamar, Venezuela, del 8 al 10 de julio de 2014.

  71. Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath 2015; 19(1):385-391. doi: 10.1007/s11325-014-1033-6.

  72. Holland AE, Fiore JF Jr, Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology 2014;19(8): 1215- 1221. doi: 10.1111/resp.12360.

  73. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathriopine and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366(21):1968- 1977. doi: 10.1056/NEJMoa1113354.

  74. Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22): 2093- 2101. doi: 10.1056/NEJMoa1401739.

  75. King TE, Bradford WZ, Castro–Bernadini S, et al.; ASCEND study group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-2092. doi: 10.1056/NEJMoa1402582.

  76. Richeldi L, Du Bois R, Raghu G, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370(22):2071-2082. doi: 10.1056/NEJMoa1402584.

  77. Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systemic review of the literature. BMC Pulm Med 2014; 14:139. doi: 10.1186/1471-2466-14-139.

  78. Nici L, ZuWallack R. Pulmonary rehabilitation: today and tomorrow. Breathe 2010;6(4):305-311. Doi: 10.1183/18106838.0604.305.

  79. Ries, AL, Bauldoff, GS, Carlin, BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131(5 Suppl):4S-42S.

  80. Nishiyama O, Taniguchi H, Kondoh Y, et al. Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. Respir Med 2007; 101(4):833-838.

  81. SwigrisJJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005;60(7):588-594.

  82. Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest 2001;120(1):209-212.

  83. Fumeaux T, Rothmeier C, Jolliet P. Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis. Intensive Care Med 2001;27(12):1868-1874.

  84. Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002;166(6):839-842.

  85. Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J 2004; 11(2):117-122.

  86. Mollica C, Paone G, Conti V, et al. Mechanical ventilation in patient with end-stage idiopathic pulmonary fibrosis. Respiration 2010;79(3):209-215. doi: 10.1159/000225932.

  87. Vianello A, Arcaro G, Battistella L, et al. Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis. J Crit Care 2014;29(4):562-567. doi: 10.1016/j.jcrc.2014.03.019.

  88. Braünlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H. Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration 2013;85(4):319-325. doi: 10.1159/000342027.

  89. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;16885):538-542.

  90. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014;23(132):220-224. doi: 10.1183/09059180.00002114.

  91. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156(10):684-691. doi: 10.7326/0003-4819-156-10-201205150-00004.

  92. Collard HR, Bradford WZ, Cottin V, et al. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J 2015;46(1):243-249. doi: 10.1183/09031936.00200614.

  93. Corte TJ, Collard H, Wells AU. Idiopathic interstitial pneumonias in 2015: A new era. Respirology 2015;20(5):697- 698. doi: 10.1111/resp.12559.

  94. Casoni GL, Tomassetti S, Cavazza A, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One 2014;9(2):e86716. doi: 10.1371/ journal.pone.0086716.

  95. Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012;18(5):441-446. doi: 10.1097/MCP.0b013e328356d03c.

  96. Loomis-King H, Flaherty KR, Moore BB. Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol 2013;13(3):377-385. doi: 10.1016/j.coph.2013.03.015.




2020     |     www.medigraphic.com